EE173 Cost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in Francecost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in France

Autor:	M Boussahoua, CS Sutherland, V Aponte Ribero, R Enache, K Le Lay, C Le Dissez, J Chevalier
Rok vydání:	2022
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 25:S87
ISSN:	1098-3015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::dd39867f26a6e417142d9574701a41ac https://doi.org/10.1016/j.jval.2022.09.423 Zobrazit plný text záznamu Full Text from ScienceDirect